Kyowa Kirin

News

Kura scores FDA okay for rival to Syndax's leukaemia drug

Kura has claimed FDA approval for oral menin inhibitor Komzifti for acute myeloid leukaemia, setting up a battle with Syndax's rival Revuforj.

Patients

How pharma is tackling new direct-to-patient programmes

At Reuters Pharma USA, executives from AstraZeneca, Gilead, Kyowa Kirin, and EVERSANA discussed the what, why, and how of direct-to-patient models.

News

Spain agrees to reimburse Orchard's gene therapy Libmeldy

Spain has agreed to reimburse Orchard Therapeutics' ex vivo gene therapy for the rare childhood disease metachromatic leukodystrophy.

News

Orchard will help Kyowa Kirin grow in gene therapy

Japan’s Kyowa Kirin has reached an agreement to buy Orchard Therapeutics of the UK in a deal valued at up to $478 million, ahead of an FDA decision on the biotech’s lead g

News

Grünenthal buys into Kyowa Kirin's mature medicines portfoli...

German pharma Grünenthal has started the process of taking ownership of 13 ageing medicines developed by Japan's Kyowa Kirin, which are currently sold by affiliate companies across Europe.<

News

Close Up Of Senior Man Suffering With Parkinsons Diesease

Kyowa Kirin drops Nourianz follow-up KW-6356 for Parkinson's

Despite reporting proof-of-concept results in a mid-stage trial, Kyowa Kirin has decided to discontinue development of its Parkinson's disease candidate KW-6356, a drug in the adenosine A2A

Kura scores FDA okay for rival to Syndax's leukaemia drug

How pharma is tackling new direct-to-patient programmes

Spain agrees to reimburse Orchard's gene therapy Libmeldy

Orchard will help Kyowa Kirin grow in gene therapy

Grünenthal buys into Kyowa Kirin's mature medicines portfoli...

Kyowa Kirin drops Nourianz follow-up KW-6356 for Parkinson's

Veraxa says delayed US listing is back on track

How to meet your physicians where they are online

Kyowa Kirin

Editor's Picks